Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment

References

• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–11. doi:10.1016/S1473-3099(20)30120-1.
   PubMed Web of Science ®Google Scholar
• Hossein-Khannazer N, Shokoohian B, Shpichka A, Aghdaei HA, Timashev P, Vosough M. Novel therapeutic approaches for treatment of COVID-19. J Mol Med (Berl). 2020;98(6):789–803. doi:10.1007/s00109-020-01927-6.
   PubMed Web of Science ®Google Scholar
• Peeples L. News Feature: avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci U S A. 2020;117(15):8218–21. doi:10.1073/pnas.2005456117.
   PubMed Web of Science ®Google Scholar
• Administration USFaD. CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19. September 25, 2021. https://wwwfdagov/drugs/coronavirus-covid-19-drugs/cder-scientific-review-documents-supporting-emergency-use-authorizations-drug-and-biological
   Google Scholar
• Peebles RS Jr., Liu MC, Lichtenstein LM, Hamilton RG, IgA I, IgM. quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays. J Immunol Methods. 1995;179(1):77–86. doi:10.1016/0022-1759(94)00275-2.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652–65. doi:10.1016/j.jmb.2007.02.024.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Structure VD. Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–92 e6. doi:10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009;106(14):5871–76. doi:10.1073/pnas.0809524106.
   PubMed Web of Science ®Google Scholar
• Bosch BJ, Van Der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–11. doi:10.1128/JVI.77.16.8801-8811.2003.
   PubMed Web of Science ®Google Scholar
• Burkard C, Verheije MH, Wicht O, van Kasteren SI, Van Kuppeveld FJ, Haagmans BL, Pelkmans L, Rottier PJ, Bosch BJ. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014;10(11):e1004502. doi:10.1371/journal.ppat.1004502.
   PubMed Web of Science ®Google Scholar
• Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan JS, Ward AB. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531(7592):118–21. doi:10.1038/nature17200.
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A. 2014;111(42):15214–19. doi:10.1073/pnas.1407087111.
   PubMed Web of Science ®Google Scholar
• Park JE, Li K, Barlan A, Fehr AR, Perlman S, McCray PB Jr., Gallagher T. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A. 2016;113(43):12262–67. doi:10.1073/pnas.1608147113.
   PubMed Web of Science ®Google Scholar
• Walls AC, Tortorici MA, Bosch BJ, Frenz B, Rottier PJM, DiMaio F, Rey FA, Veesler D. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature. 2016;531(7592):114–17. doi:10.1038/nature16988.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Flamholz A, Phillips R, Milo R SARS-CoV-2 (COVID-19) by the numbers. Elife 2020; 9.
   Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.1260419.
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–37. doi:10.1002/path.1570.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. doi:10.1038/s41368-020-0074-x.
   PubMed Web of Science ®Google Scholar
• Ding S, Liang TJ. Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal-Oral Transmission? A COVID-19 Virological and Clinical Review. Gastroenterology. 2020;159(1):53–61. doi:10.1053/j.gastro.2020.04.052.
   PubMed Web of Science ®Google Scholar
• Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, Ravelli RBG, Paul van Schayck J, Mykytyn AZ, Duimel HQ, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50–54. doi:10.1126/science.abc1669.
   PubMed Web of Science ®Google Scholar
• Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–3 e3. doi:10.1053/j.gastro.2020.02.055.
   PubMed Web of Science ®Google Scholar
• Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-9.
   PubMed Web of Science ®Google Scholar
• Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. In: Antimicrob Agents Chemother. Cesar A. Arias. eds. 2020. p. 64. ASM: Washington DC.
   Google Scholar
• Ali SO, Takas T, Nyborg A, Shoemaker K, Kallewaard NL, Chiong R, et al. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza. Antimicrob Agents Chemother. 2018;62(11):e00694-18.62.
   Web of Science ®Google Scholar
• Hershberger E, Sloan S, Narayan K, Hay CA, Smith P, Engler F, Jeeninga R, Smits S, Trevejo J, Shriver Z, et al. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine. 2019;40:574–82. doi:10.1016/j.ebiom.2018.12.051.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect. 2017;23(4):222–28. doi:10.1016/j.cmi.2017.02.009.
   PubMed Web of Science ®Google Scholar
• Palivizumab. a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998;102:531–37.
   Web of Science ®Google Scholar
• Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20(6):339–41. doi:10.1038/s41577-020-0321-6.
   PubMed Web of Science ®Google Scholar
• Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krahenbuhl S. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52(9):783–92. doi:10.1007/s40262-013-0072-7.
   PubMed Web of Science ®Google Scholar
• Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. doi:10.1186/s13054-017-1823-x.
   PubMedGoogle Scholar
• Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A, Pawelka E, Laferl H, Wenisch C, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020;8(11):1154–58. doi:10.1016/S2213-2600(20)30418-5.
   PubMed Web of Science ®Google Scholar
• Wu NC, Wilson IA. A Perspective on the Structural and Functional Constraints for Immune Evasion: insights from Influenza Virus. J Mol Biol. 2017;429(17):2694–709. doi:10.1016/j.jmb.2017.06.015.
   PubMed Web of Science ®Google Scholar
• Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11(1):2070. doi:10.1038/s41467-020-16048-4.
   PubMed Web of Science ®Google Scholar
• Liu P, Wysocki J, Souma T, Ye M, Ramirez V, Zhou B, Wilsbacher LD, Quaggin SE, Batlle D, Jin J. Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int. 2018;94(1):114–25. doi:10.1016/j.kint.2018.01.029.
   PubMed Web of Science ®Google Scholar
• Wollacott AM, Boni MF, Szretter KJ, Sloan SE, Yousofshahi M, Viswanathan K, Bedard S, Hay CA, Smith PF, Shriver Z, et al. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks. EBioMedicine. 2016;5:147–55. doi:10.1016/j.ebiom.2016.02.021.
   PubMed Web of Science ®Google Scholar
• France MM, Turner JR. The mucosal barrier at a glance. J Cell Sci 2017;130:307–14.
   PubMed Web of Science ®Google Scholar
• Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006;208(2):270–82. doi:10.1002/path.1877.
   PubMed Web of Science ®Google Scholar
• Lewis MJ, Pleass RJ, Batten MR, Atkin JD, Woof JM. Structural Requirements for the Interaction of Human IgA with the Human Polymeric Ig Receptor. The J of Immunology. 2005;175(10):6694–701. doi:10.4049/jimmunol.175.10.6694.
   PubMed Web of Science ®Google Scholar
• Fox A, Marino J, Amanat F, Krammer F, Hahn-Holbrook J, Zolla-Pazner S, et al. Evidence of a significant secretory-IgA-dominant SARS-CoV-2 immune response in human milk following recovery from COVID-19. iScience 2020; 23:101735.
   Google Scholar
• Lombana TN, Rajan S, Zorn JA, Mandikian D, Chen EC, Estevez A, Yip V, Bravo DD, Phung W, Farahi F, et al. Production, characterization, and in vivo half-life extension of polymeric IgA molecules in mice. MAbs. 2019;11(6):1122–38. doi:10.1080/19420862.2019.1622940.
   PubMed Web of Science ®Google Scholar
• Maruthachalam BV, Zwolak A, Lin-Schmidt X, Keough E, Tamot N, Venkataramani S, Geist B, Singh S, Ganesan R. Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics. MAbs. 2020;12(1):1708030. doi:10.1080/19420862.2019.1708030.
   PubMed Web of Science ®Google Scholar
• Emmerson CD, van der Vlist EJ, Braam MR, Vanlandschoot P, Merchiers P, de Haard HJ, Verrips CT, van Bergen en Henegouwen PM, Dolk E. Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH. PLoS One. 2011;6(10):e26299. doi:10.1371/journal.pone.0026299.
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther. 2009;9(3):355–68. doi:10.1517/14712590902763755.
   PubMed Web of Science ®Google Scholar
• Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem. 2004;279(17):17996–8007. doi:10.1074/jbc.M311191200.
   PubMed Web of Science ®Google Scholar
• Rossotti MA, Belanger K, Henry KA, Tanha J. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2021. doi:10.1111/febs.15809.
   PubMed Web of Science ®Google Scholar
• Tan X, Lin C, Zhang J, Khaing OMK, Fan X. Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples.  bioRxiv 2020:2020.04.20.052233.
   Google Scholar
• Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes in SARS-CoV-2 Spike: evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182(4):812-827.e19.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ, Bloom JD. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850–54. doi:10.1126/science.abf9302.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 2021;371:850-4.
   Google Scholar
• Juraszek J, Rutten L, Blokland S, Bouchier P, Voorzaat R, Ritschel T, Bakkers MJG, Renault LLR, Langedijk JPM. Stabilizing the closed SARS-CoV-2 spike trimer. Nat Commun. 2021;12(1):244. doi:10.1038/s41467-020-20321-x.
   PubMed Web of Science ®Google Scholar
• Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073–78. doi:10.1038/s41587-020-0631-z.
   PubMed Web of Science ®Google Scholar
• Huo J, Zhao Y, Ren J, Zhou D, Duyvesteyn HME, Ginn HM, Carrique L, Malinauskas T, Ruza RR, Shah PNM, et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe. 2020;28(3):497. doi:10.1016/j.chom.2020.07.002.
   PubMed Web of Science ®Google Scholar
• ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237. doi:10.1371/journal.pmed.0030237.
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol. 2019;10:1296. doi:10.3389/fimmu.2019.01296.
   PubMed Web of Science ®Google Scholar
• Snoeck V, Peters IR, Cox E. The IgA system: a comparison of structure and function in different species. Vet Res. 2006;37(3):455–67. doi:10.1051/vetres:2006010.
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020;181(4):905–13 e7. doi:10.1016/j.cell.2020.04.004.
   PubMed Web of Science ®Google Scholar
• Frohlich E, Mercuri A, Wu S, Salar-Behzadi S. Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds. Front Pharmacol. 2016;7:181. doi:10.3389/fphar.2016.00181.
   PubMed Web of Science ®Google Scholar
• Helander HF, Fandriks L. Surface area of the digestive tract - revisited. Scand J Gastroenterol. 2014;49(6):681–89. doi:10.3109/00365521.2014.898326.
   PubMed Web of Science ®Google Scholar
• Jamal M, Bangash HI, Habiba M, Lei Y, Xie T, Sun J, Wei Z, Hong Z, Shao L, Zhang Q. Immune dysregulation and system pathology in COVID-19. Virulence. 2021;12(1):918–36. doi:10.1080/21505594.2021.1898790.
   PubMed Web of Science ®Google Scholar
• Suryamohan K, Diwanji D, Stawiski EW, Gupta R, Miersch S, Liu J, Chen C, Jiang YP, Fellouse FA, Sathirapongsasuti JF, et al. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun Biol. 2021;4(1):475. doi:10.1038/s42003-021-02030-3.
   PubMed Web of Science ®Google Scholar
• Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat Biotechnol. 2020;38(7):789–91. doi:10.1038/s41587-020-0577-1.
   PubMed Web of Science ®Google Scholar
• He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–75. doi:10.1038/s41591-020-0869-5.
   PubMed Web of Science ®Google Scholar